跳至主要内容
临床试验/NCT07530510
NCT07530510尚未招募不适用

A Randomized Crossover Study of Subjective Comfort With At-Home Auto-Titrating Positive Airway Pressure (APAP): Kairos PAP (KPAP) Versus Expiratory Pressure Relief (EPR)

SleepRes Inc.0 个研究点目标入组 24 人开始时间: 2026年6月1日最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
尚未招募
发起方
入组人数
24
主要终点
Subjective comfort

研究概览

简要总结

The KPAP EPR Home is a randomized, crossover study in which subjective comfort will be compared between SleepRes APAP + KPAP and ResMed APAP + EPR. Participants will be individuals with newly diagnosed OSA who have not previously tried any PAP treatment (PAP-naïve).

Upon signing an informed consent, participants will be randomized to receiving either APAP + KPAP (delivered by a SleepRes device) or APAP + EPR (delivered by a ResMed device) for home use. Participants will be asked to use the devices (in the order of randomization) for 4 days each, with 3 days of washout in between. Participants will be blinded to the sequence order, even though they will receive machines that are not identical at each treatment. The KPAP drop will be set to the maximum level (i.e., 5 cmH2O), while EPR will be set on 3. APAP will be set on the full pressure range (i.e., 5-20 cmH2O). After each period, each individual will be asked to rate their device preference according to a 10-point visual analog (VAS) scale (i.e., 1=extremely uncomfortable treatment; 10=extremely comfortable treatment). After usage, the devices will be returned to the office and device data will be downloaded.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Crossover
主要目的
Treatment
盲法
Single (Participant)

入排标准

年龄范围
20 Years 至 80 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • BMI above 18 kg/m2, inclusive
  • Recent formal diagnosis of OSA meeting all the following criteria: AHI > 10, Central apneas < 25% of events, PLM arousal index < 15, no prior/concomitant OSA therapy
  • Subject is fluent in English and subject understands the study protocol and is willing and able to comply with study requirements and sign informed consent.
  • Participant voluntarily agrees to participate in this study and signs an Institutional Review Board (IRB)-approved informed consent prior to performing any of the study-related procedures.

排除标准

  • A female of child-bearing potential that is pregnant or intends to become pregnant.
  • Any unstable or severe medical condition of any organ system including congestive heart failure, COPD, renal failure, neuromuscular disease, etc., or at the discretion of the site Principal Investigator (PI).
  • Taking medication that may affect sleep, sleepiness, or alertness including hypnotics, sedatives, alerting agents, stimulants, anticonvulsants, etc.
  • The presence of any other sleep disorder (insomnia, periodic limb movement disorder, etc.).
  • The presence of a psychiatric disorder, including attempted suicide within 1 year prior to screening, or current suicidal ideation.
  • A serious illness or infection in the past 30 days.
  • Excessive alcohol consumption (>21 drinks/week).
  • The use of any illegal drug(s).
  • Any condition that in the investigator's opinion would present an unreasonable risk to the participant, or which would interfere with their participation in the study or confound study interpretation.

研究组 & 干预措施

APAP + KPAP

Experimental

Auto-adjusting positive airway pressure + Kairos positive airway pressure

干预措施: APAP + KPAP (Device)

APAP + EPR

Active Comparator

Auto-adjusting positive airway pressure + Expiratory pressure relief

干预措施: APAP + EPR (Device)

结局指标

主要结局

Subjective comfort

时间窗: This outcome will be evaluated after 4 days of treatment in each arm

This outcome will be evaluated through a 10 point Visual Analog Scale (VAS)

次要结局

  • P95(This outcome will be evaluated after 4 days of treatment in each arm)
  • Residual AHI(This outcome will be evaluated after 4 days of treatment in each arm)
  • Adherence (in average h/night)(This outcome will be evaluated after 4 days of treatment in each arm)

研究者

发起方
SleepRes Inc.
申办方类型
Industry
责任方
Sponsor

相似试验